stockrow
Friday 6 November 2026
Export AKTX’s income statement to Excel — free account
Akari Therapeutics PLC
AKTX Healthcare Biotechnology
- EPS
- −11.4%
- Free cash flow
- +4.51%
- Total debt
- −1.00%
Quarter to June 2026, against a year earlier
7.95
0.20
+2.58%
Follow AKTX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | (18) | (35) | (16) | (17) | (17) | (17) | (18) | (10) | (20) | (18) | (33) | +0.1% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (18) | (35) | (16) | (17) | (17) | (17) | (18) | (10) | (20) | (17) | (31) | (0.5%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (1,232.30) | (2,270.46) | (855.25) | (744.00) | (432.00) | (328.00) | (224.00) | (81.79) | (66.28) | (20.55) | (25.16) | (36.5%) | ||||||
| Cash flow | (1,675.14) | (2,025.56) | (1,169.96) | (564.12) | (429.12) | (350.96) | (275.34) | (134.25) | (42.04) | (12.56) | (6.01) | (41.9%) | ||||||
| Capex | (3.73) | (2.37) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (1,678.86) | (2,027.92) | (1,169.96) | (564.12) | (429.12) | (350.96) | (275.34) | (134.25) | (42.04) | (12.56) | (6.01) | (42.0%) | ||||||
| Book value | 2,319.90 | 1,099.62 | 161.21 | 0.33 | 237.58 | 103.44 | 22.93 | (1.87) | 74.44 | 33.66 | 10.38 | (37.5%) | ||||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | +56.8% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (25) | (32) | (23) | (13) | (17) | (19) | (22) | (16) | (13) | (11) | (11) | (9.0%) | |||||
| Capex | 0 | 0 | — | — | — | — | — | — | — | — | 0 | (32.7%) | ||||||
| Free cash flow | (25) | (32) | (23) | (13) | (17) | (19) | (22) | (16) | (13) | (11) | (11) | (9.0%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 34 | 17 | 3 | 0 | 9 | 6 | 2 | 0 | (17) | (7) | (6) | n/m | |||||
| Net debt | (44) | (28) | (4) | (3) | (14) | (9) | (13) | (4) | (2) | (5) | (7) | (22.2%) | ||||||
| Shareholders’ equity | 34 | 17 | 3 | 0 | 9 | 6 | 2 | 0 | 22 | 28 | 19 | (2.0%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (31.34) | (94.49) | (88.82) | (232.21) | (162.03) | (132.74) | (139.31) | (110.06) | (72.08) | (35.14) | (69.16) | (3.8) pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (66.73) | (45.48) | (167.93) | (45.5) pt | ||||||
| ROE | (43.81) | (138.13) | (162.51) | (1,080.27) | (363.75) | (233.27) | (483.23) | (1,281.43) | (179.92) | (68.43) | (140.09) | (24.6) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 15 | 17 | 13 | 10 | 9 | 9 | 15 | 12 | 8 | 6 | — | (9.7%) | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
Akari Therapeutics PLC vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| KYNB Kyntra Bio Inc | $14.8M | 0.1× | — (loss-making) | −209.35% (below 0%: shrinking) | n/m | −131.50% (below 0%: shrinking) | 100.14% | 1,192.27% | Compare |
| ATYR aTyr Pharma, Inc. | $14.8M | — (loss-making) | — (loss-making) | −90.75% (below 0%: shrinking) | n/m | +32.22% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ADAPY Adaptimmune Therapeutics PLC | $14.6M | — (loss-making) | — (loss-making) | −89.33% (below 0%: shrinking) | n/m | −174.72% (below 0%: shrinking) | 81.71% | (221.45%) | Compare |
| RADX Radiopharm Theranostics Limited - Sponsored ADR | $14.0M | — | — | — | — | −137.75% (below 0%: shrinking) | — | — | Compare |
| DYAI Dyadic International Inc. | $13.6M | — (loss-making) | — (loss-making) | −0.57% (below 0%: shrinking) | n/m | −1,298.54% (below 0%: shrinking) | (2.39%) | (213.73%) | Compare |
| AKTX Akari Therapeutics PLC | $13.6M | — (loss-making) | — | — | n/m | +4.51% (above 0%: growing) | 0.00% | 0.00% | |
| BCDA BioCardia, Inc. | $13.5M | — (loss-making) | — (loss-making) | −93.02% (below 0%: shrinking) | n/m | −5.15% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| LPCN Lipocine Inc. | $12.6M | — (loss-making) | — (loss-making) | +1,898.32% (above 0%: growing) | n/m | +39.46% (above 0%: growing) | 100.00% | (37.93%) | Compare |
| CASIF CASI Pharmaceuticals Inc. | $12.4M | — (loss-making) | — (loss-making) | −45.93% (below 0%: shrinking) | n/m | −23,251.69% (below 0%: shrinking) | 51.14% | (147.67%) | Compare |
| Median of peers | $13.8M | — | — | −89.33% | — | −134.62% | 100.00% | (37.93%) |